http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2227766-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b74452a889073845b47a40e23c273814 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06Q99-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
| filingDate | 2008-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e18361f511806306b5930fcda66af61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_628016df003c08332af7b11f6737af58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b0128be888c0f630891995b9c39be82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d5e1ba9cd30a64b465e9dc6bb7097c7 |
| publicationDate | 2010-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2227766-A2 |
| titleOfInvention | Systems for clinical trials |
| abstract | Methods and systems for evaluating the efficacy of a drug product whose cognitive effect is generally accepted for use in the treatment or prophylaxis of this cognitive disorder. The method comprises (1) dividing a group of patients into at least 2 subgroups based on a baseline indicator of probable progression of the disease; (2) treating the patients included in each group with the drug product for a set period of time; (3) to deduce psychometric and optionally physiological outcome measures for each group of patients treated; (4) comparing the results in (3) with the results recorded in the control group of each subgroup, optionally receiving a placebo or comparator with minimal efficacy; (5) to use the comparison in (4) to infer a measure of efficacy of the drug product. The methods and systems provided by the invention address problems such as slow worsening during treatment administration in patients with low severity of disease on the baseline indicator and biased withdrawal, in particular particular in the control group receiving the placebo / comparator. |
| priorityDate | 2007-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.